Serum anti-M&uuml;llerian hormone as a predictive marker of polycystic ovarian syndrome | Zendy

Sergio Parco | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Serum anti-Müllerian hormone as a predictive marker of polycystic ovarian syndrome

Author(s) -

Sergio Parco

Publication year - 2011

Publication title -

international journal of general medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.722

H-Index - 36

ISSN - 1178-7074

DOI - 10.2147/ijgm.s25639

Subject(s) - anti müllerian hormone , medicine , infertility , luteinizing hormone , polycystic ovary , ovarian reserve , gynecology , assisted reproductive technology , hormone , follicle stimulating hormone , female infertility , in vitro fertilisation , andrology , endocrinology , biology , embryo , pregnancy , obesity , insulin resistance , genetics , microbiology and biotechnology

The anti-Müllerian hormone (AMH) is a dimeric protein secreted by the female ovaries and has two fundamental roles in follicle genesis. It delays the entrance of the primordial follicle into the pool of follicles in growth and diminishes the sensitivity of the ovarian follicle towards follicle-stimulating hormone (FSH). The purpose of this work was to study the AMH (nv 2.0-6.8 ng/mL) as a marker during assisted reproductive technology (ART), in order to identify cases of infertility due to polycystic ovarian syndrome (PCOS). This syndrome affects 10% of women with infertility problems, and a new biological marker could be useful to general practitioners of internal medicine to help generate the suspicion of PCOS so that they can refer the patient to the gynecologist for confirmation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research